Calliditas - DNB initiates coverage with SEK265-315 Price target
Rarity value
Powered by Redeye, we initiate coverage on specialist pharma company Calliditas Therapeutics (Calliditas), which we view as a front-runner in the rare-diseases market, with a fair value of SEK265–315. The core value driver is the drug Nefecon, approved in the US as Tarpeyo, and in Europe as Kinpeygo. Nefecon is an effective candidate for IgAn patients at high risk of disease progression. Our bull-case value is SEK448 and our bear-case value is SEK76.
Powered by Redeye, we initiate coverage on specialist pharma company Calliditas Therapeutics (Calliditas), which we view as a front-runner in the rare-diseases market, with a fair value of SEK265–315. The core value driver is the drug Nefecon, approved in the US as Tarpeyo, and in Europe as Kinpeygo. Nefecon is an effective candidate for IgAn patients at high risk of disease progression. Our bull-case value is SEK448 and our bear-case value is SEK76.
NordicGuy
20.10.2023 kl 13:42
176
Calliditas Therapeutics has been selling in the US since 1Q23. Its annualised sales exceed USD100 million. Not a bad product launch. Two material catalysts expected in Q4 - China approval and full US approval. Both should accelerate sales growth.
Full investment thesis and Carnegie summary:
https://fitinvestmentideas.com/2023/10/20/carnegie-on-calliditas-us-and-china-approvals-due-in-q4/
Full investment thesis and Carnegie summary:
https://fitinvestmentideas.com/2023/10/20/carnegie-on-calliditas-us-and-china-approvals-due-in-q4/